ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results

Author's Avatar
May 06, 2022

ImmunoGen%2C+Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2022.